Owen Roberts BComm

Owen is the Chief Executive officer of both Nobelex Biotech Inc and M4K Pharma. M4K Pharma is a company dedicated to finding affordable new medicines for children’s orphan diseases. Partnering with academics, foundations and industry groups to fund its drug discovery and drug development programs, M4K Pharma uses open science principles of data sharing to encourage research collaborations and to reduce the cost of its programs. Prior to founding M4K Pharma in 2017 and Nobelex in 2014, he was a co-founder of Affinium Pharmaceuticals, a privately held, clinical stage, antibiotic company. At Affinium, he was the CFO and led the company’s business development until the successful sale of Affinium's antibiotic programs to Debiopharm International, S.A. in February 2014. Prior to Affinium, In 1998, Owen helped create Borealis Biosciences, one of two companies which would merge to form Affinium in 2000. A graduate of McGill University, Owen is also a Chartered Financial Analyst​.